Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
van de Berg, S E JPelzer, P T
van der Land, A J
Abdrakhmanova, E
Ozi, A Muhammad
Arias, M
Cook-Scalise, S
Dravniece, G
Gebhard, A
Juneja, S
Handayani, R
Kappel, D
Kimerling, M
Koppelaar, I
Malhotra, S
Myrzaliev, B
Nsa, B
Sugiharto, J
Engel, N
Mulder, C
van den Hof, S
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.Published in
BMC Public Health 2021; 21(1):1404PMID
34271884ae974a485f413a2113503eed53cd6c53
10.1186/s12889-021-11427-y
Scopus Count
Collections